Label-Free Detection Market Size, Share, and Industry Analysis, By Product (Instrument, Consumables, and Software), By Technology (Biolayer Interferometry (BLI), Surface Plasmon Resonance (SPR), Grating-Coupled Interferometry (GCI), and Others), By Application (Drug Discovery & Development, Pharmaceutical & Biological Research, and Others), By End-user (Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs), Pharmaceutical & Biotechnology Companies, and Others), and Regional Forecast, 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI114776

Label-Free Detection Market Size & Future Outlook

The global label-free detection market size was valued at USD 2.15 billion in 2025. The market is projected to grow from USD 2.41 billion in 2026 to USD 6.04 billion by 2034, exhibiting a CAGR of 12.15% during the forecast period.

The global label-free detection market is projected to experience substantial growth during the forecast period. The label-free detection technique involves the direct study of native molecules, such as proteins, without using artificial probes or labels. The label-free detection, also known as label-free sensing that uses optical biosensors to measure the changes that occur upon analyte binding to a ligand immobilized on a biosensor surface. The increasing market players' focus on new product launches is one of the important factors driving market growth.

For example, in February 2022, Bruker announced the launch of its timsTOF MALDI PharmaPulse (timsTOF MPP) system, a novel high-end solution for unbiased, deep HTS and uHTS based on label-free mass spectrometry.

Moreover, the advancements in life science research and drug discovery, coupled with the increasing demand for more efficient and sensitive detection methods, are some of the additional factors supplementing the market growth.

Label-Free Detection Market Driver

The Growing Focus on the Development of Biologics and Biosimilars to Increase the Demand for Label-Free Detection, thereby Driving Market Growth

The rising focus of companies on the development of biologics is one of the major factors driving market growth. Biologics are complex therapeutic products that require high-sensitivity tools for molecular interaction analysis, quality control, and drug development. The label-free detection technologies, such as surface plasmon resonance (SPR), biolayer interferometry (BLI), etc., play an important role in analyzing antibody-antigen, protein-protein, and ligand-receptor interactions, which are essential in the development and characterization of biologic therapies.

The rising number of biologic approvals worldwide is driving market growth. For instance, as per the data published by MDPI in January 2025, the U.S. Food and Drug Administration (FDA) approved 13 biologics in 2020 and 16 biologics in 2024.

Moreover, the development of biosimilars requires a detailed comparison to the reference biologic, including molecular similarities and binding kinetics, where the label-free detection technique offers greater efficiency. The expanding pipeline of biologics and biosimilars is increasing the adoption of label-free detection systems, thereby driving market growth.

The U.S. Food and Drug Administration (FDA) Approved Biologics, 2019-2023

For example, as per the data provided by MDPI in January 2025, the U.S. Food and Drug Administration (FDA) approved 15 biologics in 2022 and 17 biologics in 2023.

Label-Free Detection Market Restraint

The High Cost of Instruments and their Maintenance is Restricting the Market Growth

The label-free detection systems, especially those based on surface plasmon resonance (SPR) and biolayer interferometry (BLI), are highly sophisticated and expensive. The initial purchase cost of the instrument, along with its maintenance cost and software licenses, is creating a financial burden, especially for smaller companies and academic institutes in low-income countries.

For example, as per the data provided by Excedr, the Reichert SPR systems typically cost from USD 100,000.0 to USD 250,000.0, depending on the type of model.
Also, as per the same source, the price of Biacore SPR systems, provided by Bruker are typically ranges from USD 150,000.0 to USD 500,000.0, with the higher-end models offering features such as high-throughput screening and complex kinetic analysis.

Therefore, such a high cost of instruments limits their adoption in countries with constrained healthcare budgets is hindering market growth.

Label-Free Detection Market Opportunity

The Increasing Government Funding for Biomedical Research Creates New Opportunities for Market Growth

The increasing market players' focus on receiving government funding for biomedical research is creating growth opportunities for the label-free detection market. The government authorities across the globe are highly investing in biomedical and life science research, where label-free detection technologies play an important role due to their ability to provide high-throughput analysis in real time.

For example, as per the data provided by the United for Medical Research in March 2025, the National Institute of Health (NIH) is the largest public funder of biomedical research in the world. NIH awarded USD 37.81 billion in extramural research funding to researchers in all 50 U.S. states and the District of Columbia in 2023.

Furthermore, the large-scale government initiatives such as the European Union's Horizon program, with a funding of USD 101.19 billion (2021-2027), are enabling public-private companies' collaborations focused on strengthening research activities for the development of innovative solutions.

Such government funding is increasing R&D activities and creating significant opportunities for market growth.

Key Insights

The report covers the following key insights:

Technological Advancements in Label-Free Detection Systems.
New Product Launches, by Key Players
Key industry developments (Mergers, acquisitions, partnerships, etc.)

Segmentation

By Product	By Technology	By Application	By End-user	By Region
Instrument Consumables Software	Biolayer Interferometry (BLI) Surface Plasmon Resonance (SPR) Grating-Coupled Interferometry (GCI) Others	Drug Discovery & Development Pharmaceutical & Biological Research Others	Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs) Pharmaceutical & Biotechnology Companies Others	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Analysis by Product

Based on the product, the market is segmented into instruments, consumables, and software. The instrument segment is anticipated to grow at the highest CAGR from 2025 to 2032. The increasing market players' focus on new product launches to provide researchers with the instrument with its most advanced detection capabilities is one of the important factors driving segmental growth during the forecast period.

For example, in May 2025, Sartorius AG launched the Octet R8e system in the global market. This system provides real-time, label-free biomolecular interaction analysis with unprecedented sensitivity and efficiency.

Analysis by Technology

On the basis of technology, the market is segmented into biolayer interferometry (BLI), surface plasmon resonance (SPR), grating-coupled interferometry (GCI), and others. The biolayer interferometry (BLI) segment is anticipated to grow at the highest CAGR from 2025 to 2032, owing to the increasing launch of biolayer interferometry (BLI) technology-based systems.

For example, in May 2021, Sartorius AG launched the new high-performance Octet R series of systems, the latest improvement in the company's line of label-free analytical products.

Analysis by Application

Based on the application, the market is categorized into drug discovery & development, pharmaceutical & biological research, and others. The pharmaceutical & biological research segment is anticipated to grow at a significant CAGR from 2025 to 2032. The increasing market players' focus on the launch of novel products at medical events to enhance research activities by using advanced analytical systems, providing label-free detection, is one of the important factors driving segmental growth during the forecast period.

For example, in August 2022, Bruker launched the new nanoElute 2 nano-LC system at the International Mass Spectrometry Conference (IMSC 2022) to enhance research in protein-protein interactions (PPIs) and metaproteomics applications.

Analysis by End-user

In terms of end-user, the market is divided into contract research organizations (CROs) & contract manufacturing organizations (CMOs), pharmaceutical & biotechnology companies, and others. The contract research organizations (CROs) & contract manufacturing organizations (CMOs) segment is anticipated to grow at a significant CAGR from 2025 to 2032. The opening of new CROs providing manufacturing, clinical research, and clinical supply chain services for small molecule, biologics, and cell and gene therapies worldwide is one of the prominent factors enhancing the segmental growth throughout the forecast period.

For example, in October 2024, Franklin Biolabs launched in Pennsylvania, U.S., to provide genetic medicines CRO services. Franklin Biolabs and its team of over 130 experts offer a full range of services, providing comprehensive solutions from discovery to development.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization to gain extensive market insights.

North America accounted for the dominant share of the global label-free detection market in 2024. The market in this region is expected to grow significantly from 2025 to 2032. The established healthcare infrastructure and increasing government authorities' focus on providing funding for medical research activities are some of the important factors driving market growth in this region.

For example, as per the data provided by the United for Medical Research in March 2025, the National Institutes of Health (NIH) awarded USD 36.94 billion in extramural research funding to researchers in all 50 U.S. states and the District of Columbia in 2024.

The market in Europe is anticipated to grow moderately during the forecast period. The presence of major market players, such as Malvern Panalytical Ltd, BioNavis, XanTec bioanalytics GmbH, and Sartorius AG, providing advanced analytical solutions used to perform label-free detection, is driving market growth across the European region.

Key Players Covered

The global label-free detection market consists of companies such as Sartorius AG, Malvern Panalytical Ltd, Bruker, and Thermo Fisher Scientific Inc.

The report includes the profiles of the following key players:

Sartorius AG (Germany)
Malvern Panalytical Ltd (U.K.)
HORIBA, Ltd. (Japan)
BioNavis (Finland)
Corning Incorporated (U.S.)
XanTec bioanalytics GmbH (Germany)
Bruker (U.S.)
Nicoya Lifesciences Inc. (Canada)
Thermo Fisher Scientific Inc. (U.S.)

Key Industry Developments

In June 2025, Bruker announced the launch of the proteoElute, a state-of-the-art nanoflow liquid chromatography (LC) system designed for robust and ultra-sensitive multiomics applications.
In May 2022, Sartorius AG launched the Octet SF3 SPR System, a proprietary fluidic-free instrument platform for real-time, label-free analysis of biomolecular interactions.
In October 2021, Gator Bio, Inc. announced the launch of the Gator SMAP probe and Gator mFC probe for GatorPrime and GatorPlus biolayer interferometry (BLI) systems in the global market.